DecisionView's StudyOptimizer Now Available as Software-as-a-Service
DecisionView (San Francisco, CA) announced today that its Web-based enrollment application, StudyOptimizer, will now be available as Software-as-a-Service (SAS). In addition to faster deployment, the pay-as-you-go version will deliver a lower cost of ownership, says the company.
"We realized the importance of accelerating the adoption of our solution, so that customers could implement corrective actions in their enrollment processes as quickly as possible," said Jim Scullion, Chief Executive Officer of DecisionView. "With the launch of this new offering, companies can leverage the planning and forecasting capabilities of StudyOptimizer in a shorter time frame, even on a single trial."
The SAS model will be hosted in a SAS70 certified infrastructure and is available now.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
